Should patients stop their biologic treatment during the COVID-19 pandemic

Bashyam, Arjun M.; Feldman, Steven R.

doi:10.1080/09546634.2020.1742438

Cited by 63 publications

(75 citation statements)

References 15 publications

(14 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Clinical trials of hydroxychloroquine treatment for COVID-19 pneumonia have shown positive preliminary outcomes in China. Unfortunately, the corticosteroid treatments commonly used in clinical practice for influenza virus such as acyclovir, ganciclovir, ribavirin and methylprednisolone, as well as neuraminidase inhibitors including peramivir, oseltamivir and zanamivir, are invalid against COVID-19 and are not recommended [18].…”

Section: Nmnimentioning

confidence: 99%

Mutated COVID-19 may foretell a great risk for mankind in the future

Dawood

2020

New Microbes and New Infections

152

128

View full text Add to dashboard Cite

Coronavirus disease 2019 SARS-CoV-2 (COVID-19) is a zoonotic virus causing a variety of severe respiratory diseases. SARS-CoV-2 is closest to SARS-CoV and MERS-CoV in structure. The high prevalence of COVID-19 is a result of a lack of symptoms at onset. Our study aimed to present an overview of the virus in terms of structure, epidemiology, symptoms, treatment and prevention. Whole genome sequences and some viral proteins were investigated to determine gaps and changes in alternation of nucleotides and amino acid sequences. We evaluate 11 complete genome sequences of different coronaviruses using BAST and MAFFT software. We also selected seven types of structural proteins. We conclude that COVID-19 might produce new mutations, specifically in glycoproteins, so caution and complete preparation by health authorities is required.

show abstract

Section: Nmnimentioning

confidence: 99%

Mutated COVID-19 may foretell a great risk for mankind in the future

Dawood

2020

New Microbes and New Infections

152

128

View full text Add to dashboard Cite

show abstract

“…There is no available evidence that supports discontinuation of biologic treatment of psoriasis for most patients simply because of the risk of infection [24]. According to the results of randomized clinical trials of biological agents in psoriasis, the rates of nasopharyngitis and upper respiratory tract infections are similar to placebo [25].…”

mentioning

confidence: 99%

Managing Cutaneous Immune-Mediated Diseases During the COVID-19 Pandemic

Torres

Puig

2020

Am J Clin Dermatol

View full text Add to dashboard Cite

“…Although treatment with these agents could put the patients at a higher risk for COVID-19, symptoms manifested milder than the others. So, these drugs might be useful in reducing the severity of COVID-19 [15].…”

Section: Discussionmentioning

confidence: 99%

Prevalence of Coronavirus Disease 2019 in Rheumatic Patients and Evaluation of The Effect of Disease-Modifying Anti-Rheumatic Drugs

Moradi¹,

Mohammadi²,

Vafaeimanesh

et al. 2020

Preprint

View full text Add to dashboard Cite

Background: One of the most controversial issues among rheumatologists is the best approach to managing a rheumatic patient (RP) with coronavirus disease 2019 (COVID-19).Objectives: This study aims to evaluate the prevalence of COVID-19 in RPs and compare it to thegeneral population (healthy individuals). Besides, it assesses the incidence of COVID-19 based on rheumatologic diseases (RDs) categories and immunosuppressive (IS) drug history.Methods: In a cross-sectional study, all RPs of the rheumatology clinic of Shahid BeheshtiHospital, Qom, Iran were included (the case group), and the prevalence of COVID-19 was compared to that in healthy individuals (the control group), between December 1, 2019, andFebruary 29, 2020. Qom city was the first city in Iran in which COVID-19 was identified and spread rapidly. The participants were recruited from hospital records for the case group and QomHealth Network’s database for the control group.Results: The prevalence of COVID-19 is significantly less in RPs than in the healthy population.Moreover, patients who were under treatment with biologic diseas-modifying anti-rheumatic drugs(DMARDs) and IS drugs had milder symptoms in the case of COVID-19. Two RPs died from COVID-19, both of whom had granulomatosis and polyangiitis (GPA).Conclusion: The prevalence of COVID-19 in the RPs was lower than the general population, which was determined to be associated with more adherence to the quarantine and social distancing rules by RPs. Besides, using leflunomide (a DMARD) and IS drugs might have a protective effect against severe COVID-19.

show abstract

Should patients stop their biologic treatment during the COVID-19 pandemic

Cited by 63 publications

References 15 publications

Mutated COVID-19 may foretell a great risk for mankind in the future

Mutated COVID-19 may foretell a great risk for mankind in the future

Managing Cutaneous Immune-Mediated Diseases During the COVID-19 Pandemic

Prevalence of Coronavirus Disease 2019 in Rheumatic Patients and Evaluation of The Effect of Disease-Modifying Anti-Rheumatic Drugs

Contact Info

Product

Resources

About